Share price · NBP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NBP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+9.8%
- 3 Nov 2026-5.6%
Nothing announced by NBP that day or the session before.
- 2 Nov 2026-10.5%
Nothing announced by NBP that day or the session before.
- 26 Oct 2026-11.3%
- 20 Oct 2026+9.6%
- 24 Sep 2026-5.2%
Nothing announced by NBP that day or the session before.
- 29 Jun 2026+20.7%
- 6 May 2026-5.5%
Nothing announced by NBP that day or the session before.
- 30 Mar 2026-11.8%
Nothing announced by NBP that day or the session before.
- 5 Mar 2026+17.0%
Nothing announced by NBP that day or the session before.
Share of unusual movement by asset
For each asset, the share of NBP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | CD73Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | Claudin 18.2 (CLDN18.2) x 4-1BBMultispecific antibody | Gastric Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
August 2028 (1)
What to watch
2030 (1)
March 2030 (1)
What to watch
Financial reports
Quarterly & interim (7)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | $0 | $3.3M | $166M | $5.5M | report ↗ |
NovaBridge Biosciences reported revenue of $0M for 2025-Q2, with R&D spend of $3.3M, down 69.4% YoY. Cash and equivalents stood at $165.6M, while net income/loss was not disclosed and quarterly net burn was $5.5M. No analyst consensus comparison was provided.
The material disclosed no financial guidance or pipeline/clinical developments. The key event was a proposed change of the company’s name from I-Mab to NovaBridge Biosciences, along with the adoption of a seventh amended and restated memorandum and articles of association, to be voted on at an extraordinary general meeting on October 24, 2025.
View 6 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q1 | $0 | $0.8M | $169M | $3.2M | report ↗ |
| 2024-Q3 | $0 | $4.5M | $184M | $20M | report ↗ |
| 2024-H1 | $0 | $11M | $208M | — | report ↗ |
| 2023-H1 | $2.7M | $62M | $415M | $107M | report ↗ |
| 2022-H1 | $7.7M | $68M | $586M | $156M | report ↗ |
| 2021-H1 | $2.8M | $92M | $739M | $167M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $63M | $211M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($663K), 7 sales ($154K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | Hagler Mark Arnold · Chief Commercial Officer | Open-market purchase | 184,000 | $0.38 | $70K | Form 4 |
| 2026-11-17 | Hagler Mark Arnold · Chief Commercial Officer | Open-market purchase | 46,000 | $0.34 | $16K | Form 4 |
| 2026-10-15 | Woo Ian Ying · director | Option exercise | 13,271 | — | — | Form 4 |
| 2026-10-15 | Woo Ian Ying · director | Option exercise (derivative) | 5,770 | — | — | Form 4 |
| 2026-09-18 | Dennis Phillip Andrew · Chief Medical Officer | Open-market sale | 8,209 | $0.71 | $6K | Form 4 |
| 2026-09-17 | Dennis Phillip Andrew · Chief Medical Officer | Option exercise | 23,695 | — | — | Form 4 |
| 2026-09-17 | Dennis Phillip Andrew · Chief Medical Officer | Option exercise (derivative) | 10,302 | — | — | Form 4 |
| 2026-09-09 | Cao Sean Wuxiong · Chief Bus. Development Officer | Open-market sale | 107,978 | $0.74 | $80K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 48 reporting institutions held 29.3M shares ($71.8M, 25.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 6,032,650 | $14.8M |
| 2 | HHLR ADVISORS, LTD. | 5,980,568 | $14.7M |
| 3 | MORGAN STANLEY | 3,838,198 | $9.4M |
| 4 | Siren, L.L.C. | 3,000,000 | $7.4M |
| 5 | AIHC Capital Management Ltd | 2,262,933 | $5.6M |
| 6 | Point72 Asset Management, L.P. | 1,389,403 | $3.4M |
| 7 | Candriam S.C.A. | 1,132,563 | $2.8M |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,000,000 | $2.5M |
| 9 | Woodline Partners LP | 700,000 | $1.7M |
| 10 | BlackRock, Inc. | 627,496 | $1.5M |
| 11 | Exome Asset Management LLC | 576,960 | $1.4M |
| 12 | STATE STREET CORP | 370,107 | $910K |
| 13 | Fiera Capital Corp | 315,681 | $777K |
| 14 | BARCLAYS PLC | 299,299 | $736K |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 272,412 | $670K |